InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,242.00
(
0.05%
)
Dow Jones
39,872.99
(
0.00%
)
Brent Oil
81.87
(
-0.70%
)
Bitcoin
69,988.47
(
-0.20%
)
Post# of 251889
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: oc631 post# 169359

Tuesday, 11/05/2013 11:03:54 AM

Tuesday, November 05, 2013 11:03:54 AM

Post# of 251889
GILD's SVR12 results from the LONESTAR trial 8 weeks or 12 weeks

Interpretation
These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV, irrespective of treatment history or the presence of compensated cirrhosis. Further clinical trials are needed to establish the best treatment duration and to further assess the contribution of ribavirin.



http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62121-2/abstract
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up